BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boike J, Dejulio T. Severe Esophagitis and Gastritis from Nivolumab Therapy. ACG Case Rep J. 2017;4:e57. [PMID: 28459081 DOI: 10.14309/crj.2017.57] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056-67. [DOI: 10.1136/gutjnl-2018-316948] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 24.7] [Reference Citation Analysis]
2 Hamamoto Y, Shin N, Hoshino T, Kanai T. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. Future Oncol 2018;14:3187-98. [PMID: 30188189 DOI: 10.2217/fon-2018-0509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
3 Yoon SY, Han JJ, Baek SK, Kim HJ, Maeng CH. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study. Lung Cancer 2020;147:21-5. [PMID: 32652370 DOI: 10.1016/j.lungcan.2020.06.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Pittman ME, Hissong E, Katz PO, Yantiss RK. Lymphocyte-predominant Esophagitis: A Distinct and Likely Immune-mediated Disorder Encompassing Lymphocytic and Lichenoid Esophagitis. American Journal of Surgical Pathology 2020;44:198-205. [DOI: 10.1097/pas.0000000000001394] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer 2018;6:156. [PMID: 30587227 DOI: 10.1186/s40425-018-0481-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 10.7] [Reference Citation Analysis]
6 Collins M, Soularue E, Marthey L, Carbonnel F. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:1393-1403.e1. [PMID: 32007539 DOI: 10.1016/j.cgh.2020.01.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
7 Cardona AF, Ruiz-Patiño A, Ricaurte L, Zatarain-Barrón ZL, Barrón F, Arrieta O. Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab - Diagnostic and Therapeutic Challenge: A Case Report. Case Rep Oncol 2020;13:314-20. [PMID: 32308598 DOI: 10.1159/000505968] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kröner PT, Mody K, Farraye FA. Immune checkpoint inhibitor-related luminal GI adverse events. Gastrointest Endosc 2019;90:881-92. [PMID: 31526811 DOI: 10.1016/j.gie.2019.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Melanoma Res. 2018;28:645-647. [PMID: 30256271 DOI: 10.1097/cmr.0000000000000502] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
10 Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier RS, Richards DM, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019;54:538-545. [PMID: 31079556 DOI: 10.1080/00365521.2019.1594356] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
11 Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis - What to do and when? Best Pract Res Clin Gastroenterol 2020;48-49:101703. [PMID: 33317787 DOI: 10.1016/j.bpg.2020.101703] [Reference Citation Analysis]
12 Nishimura Y, Yasuda M, Ocho K, Iwamuro M, Yamasaki O, Tanaka T, Otsuka F. Severe Gastritis after Administration of Nivolumab and Ipilimumab. Case Rep Oncol. 2018;11:549-556. [PMID: 30186138 DOI: 10.1159/000491862] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
13 Qualls D, Seethapathy H, Bates H, Tajmir S, Heidari P, Endres P, Reynolds K, Lawrence D, Sise M. Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis. J Immunother Cancer 2019;7:356. [PMID: 31864416 DOI: 10.1186/s40425-019-0820-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Acero Brand FZ, Suter N, Adam JP, Faulques B, Maietta A, Soulières D, Blais N. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. J Immunother Cancer. 2018;6:22. [PMID: 29548299 DOI: 10.1186/s40425-018-0332-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
15 Pavlick A, Weber J. Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. In: Balch CM, Atkins MB, Garbe C, Gershenwald JE, Halpern AC, Kirkwood JM, Mcarthur GA, Thompson JF, Sober AJ, editors. Cutaneous Melanoma. Cham: Springer International Publishing; 2020. pp. 1187-214. [DOI: 10.1007/978-3-030-05070-2_60] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Arora K, Zhang ML, Goiburú-chenu MB, England J. Pathology of immune checkpoint inhibitor-induced injury of the gastrointestinal tract and hepatobiliary system. Diagnostic Histopathology 2021;27:62-8. [DOI: 10.1016/j.mpdhp.2020.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dougan M. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. Curr Gastroenterol Rep 2020;22. [DOI: 10.1007/s11894-020-0752-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
18 Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, Chaughtai S, Patel S, Patel T, Bramson J, Gupta V, Levitt M, Asif A, Hossain MA. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study. J Clin Med Res. 2019;11:225-236. [PMID: 30937112 DOI: 10.14740/jocmr3750] [Cited by in Crossref: 67] [Cited by in F6Publishing: 50] [Article Influence: 33.5] [Reference Citation Analysis]
19 Omotehara S, Nishida M, Yamanashi K, Sakurai K, Katsurada T, Komatsu Y, Shimizu A, Shibuya H, Shinagawa N, Sugita J, Teshima T. A case of immune checkpoint inhibitor-associated gastroenteritis detected by ultrasonography. J Clin Ultrasound 2021;49:605-9. [PMID: 33580597 DOI: 10.1002/jcu.22975] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wright AP, Piper MS, Bishu S, Stidham RW. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 2019;49:1474-83. [PMID: 31035308 DOI: 10.1111/apt.15263] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
21 Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer 2020;28:6129-43. [PMID: 32856210 DOI: 10.1007/s00520-020-05707-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
22 Kim H, Ha SY, Kim J, Kang M, Lee J. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma. Curr Oncol 2020;27:e436-9. [PMID: 32905211 DOI: 10.3747/co.27.6163] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
24 Gaffuri P, Espeli V, Fulciniti F, Paone G, Bergmann M. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica 2019;111:92-7. [PMID: 31748755 DOI: 10.32074/1591-951X-24-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
25 Sheth H, Pragya R, Kovale S, Deshpande M, Mistry R, Shreenivas A, Limaye S. Oral mucositis—case series of a rare adverse effect associated with immunotherapy. Support Care Cancer 2021;29:4705-9. [DOI: 10.1007/s00520-021-05993-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. [PMID: 34172516 DOI: 10.1136/jitc-2021-002435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Onuki T, Morita E, Sakamoto N, Nagai Y, Sata M, Hagiwara K. Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirol Case Rep 2018;6:e00334. [PMID: 30065841 DOI: 10.1002/rcr2.334] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Rovedatti L, Lenti MV, Vanoli A, Feltri M, De Grazia F, Di Sabatino A. Nivolumab-associated active neutrophilic gastritis. J Clin Pathol 2020;73:605-6. [PMID: 32161070 DOI: 10.1136/jclinpath-2020-206540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]